Actinium Pharmaceuticals (Delaware) (ATNM) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Actinium Pharmaceuticals (Delaware) (ATNM) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 26.7% versus a loss of 87.4%. Over five years, ATNM leads with a -86.3% price change compared with -100.0% for RNAZ. Actinium Pharmaceuticals (Delaware) is the larger company by market cap ($34.6 million vs $31.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ATNM | RNAZ |
|---|---|---|
| Share price | $1.10 | $1.86 |
| Market cap | $34.59M | $31.49M |
| 1-day change | +1.85% | +8.77% |
| YTD return | -19.12% | -72.77% |
| 1-year return | -26.67% | -87.42% |
| 5-year return | -86.32% | -100.00% |
| P/E ratio (TTM) | 3.06 | — |
| EPS (TTM) | $0.36 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.74 | $15.94 |
| 52-week low | $0.735 | $1.52 |
| Distance from 52-week high | -36.78% | -88.33% |
| Analyst consensus | none | — |
| Avg. price target upside | +227.27% | — |
| Average volume | 139.78K | 50.19K |
| Shares outstanding | 31.44M | 16.93M |
| Employees | 27 | 12 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ATNM has outperformed RNAZ by 60.7 percentage points over the past year.
About Actinium Pharmaceuticals (Delaware)
ATNM stock →Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
ATNM vs RNAZ FAQ
Which is bigger, Actinium Pharmaceuticals (Delaware) or TransCode Therapeutics?
Actinium Pharmaceuticals (Delaware) (ATNM) is larger, with a market capitalization of $34.59M compared with $31.49M for TransCode Therapeutics (RNAZ).
Which stock has performed better over the past year, ATNM or RNAZ?
ATNM returned -26.67% over the past 12 months, compared with -87.42% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are Actinium Pharmaceuticals (Delaware) and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.